Cargando…

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

Objective To assess whether vaccination against human papillomavirus (HPV) increases the risk of miscarriage. Design Pooled analysis of two multicentre, phase three masked randomised controlled trials Setting Multicentre trials in several continents and in Costa Rica. Participants 26 130 women aged...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wacholder, Sholom, Chen, Bingshu Eric, Wilcox, Allen, Macones, George, Gonzalez, Paula, Befano, Brian, Hildesheim, Allan, Rodríguez, Ana Cecilia, Solomon, Diane, Herrero, Rolando, Schiffman, Mark
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831171/ https://www.ncbi.nlm.nih.gov/pubmed/20197322 http://dx.doi.org/10.1136/bmj.c712

Ejemplares similares

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial
por: Panagiotou, Orestis A, et al.
Publicado: (2015)

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
por: Kreimer, Aimée R., et al.
Publicado: (2011)

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
por: Herrero, Rolando, et al.
Publicado: (2013)

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
por: Hildesheim, Allan, et al.
Publicado: (2016)

A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection
por: Clarke, Megan A, et al.
Publicado: (2012)

Determinants of seropositivity among HPV-16/18 DNA positive young women
por: Porras, Carolina, et al.
Publicado: (2010)

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica
por: Clarke, Megan, et al.
Publicado: (2013)

HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays
por: Lin, Shih-Wen, et al.
Publicado: (2013)

Sequence Imputation of HPV16 Genomes for Genetic Association Studies
por: Smith, Benjamin, et al.
Publicado: (2011)

Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer
por: Wang, Sophia S., et al.
Publicado: (2010)

Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
por: Castle, Philip E, et al.
Publicado: (2009)

Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer
por: Safaeian, Mahboobeh, et al.
Publicado: (2012)

Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays
por: Robbins, Hilary A., et al.
Publicado: (2014)

Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67
por: Chen, Zigui, et al.
Publicado: (2011)

Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
por: Kreimer, Aimée R., et al.
Publicado: (2018)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus
por: Robbins, Hilary A, et al.
Publicado: (2014)

HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial
por: Tsang, Sabrina H., et al.
Publicado: (2022)

Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection
por: Cullen, Michael, et al.
Publicado: (2015)

Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan
por: Anwari, Palwasha, et al.
Publicado: (2020)

A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria
por: Clarke, Megan A, et al.
Publicado: (2011)

Assessment of Human Papillomavirus in Lung Tumor Tissue
por: Koshiol, Jill, et al.
Publicado: (2011)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
por: Harper, Diane M., et al.
Publicado: (2011)

Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70
por: Chen, Zigui, et al.
Publicado: (2013)

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
por: Kavanagh, K, et al.
Publicado: (2014)

HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica
por: Hildesheim, A, et al.
Publicado: (2001)

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica
por: Wang, S S, et al.
Publicado: (2004)

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection
por: Beachler, Daniel C., et al.
Publicado: (2016)

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica
por: Wang, S S, et al.
Publicado: (2003)

Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China
por: He, Hongchang, et al.
Publicado: (2016)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study
por: Mesher, David, et al.
Publicado: (2016)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Human papillomavirus (HPV) 16 infection is not detected in rectal carcinoma
por: Martins, Sandra F., et al.
Publicado: (2020)

Erratum to: Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2020)

Signature sequence validation of human papillomavirus type 16 (HPV-16) in clinical specimens
por: Lee, Sin Hang, et al.
Publicado: (2009)

Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule
por: Hoes, Joske, et al.
Publicado: (2021)

Excess mortality from COVID 19 in Costa Rica: a registry based study using Poisson regression
por: Fantin, Romain, et al.
Publicado: (2023)

T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study
por: Lang Kuhs, Krystle A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0q5gcn4hhqtnt5m1slclpk6vbt